Some bleeding or spotting in the first months after starting a new continuous-combined hormone therapy regimen is genuinely common, and does not automatically mean something has gone wrong.

In a randomized trial of continuous-combined hormone therapy, unscheduled bleeding or spotting was reported by about a third of women (37%) at three months, still close to three in ten (30%) at six months, down to about a quarter (26%) at a year, and to a small minority (7%) by eighteen months, as the endometrium adjusts from cyclic to steady hormone exposure. Women who start treatment with a slightly thicker baseline endometrium tend to have more bleeding days before settling into no bleeding at all. That said, 'it's probably just the adjustment period' is not something you should have to accept without any actual look. Current guidance on evaluating bleeding in postmenopausal women, including women already established on hormone therapy, treats bleeding that continues well past the first several months, bleeding that restarts after a stretch of no bleeding, heavy bleeding, or bleeding with pain as reasons for real evaluation, typically an ultrasound and, depending on findings, endometrial tissue sampling, rather than reassurance without any testing. There is active, current debate among specialists about exactly how quickly to move from ultrasound to tissue sampling, but there is no debate that new or changed bleeding on established hormone therapy deserves an actual evaluation and a documented follow-up plan, not a dismissal.

What to know about this answer

There is real, current debate in gynecology about exactly how aggressively to investigate postmenopausal bleeding, including bleeding in women already established on hormone therapy. One position, reflected in the most recent revision of ACOG guidance, pushes toward routine endometrial tissue sampling rather than relying on ultrasound measurements alone, partly because some aggressive endometrial cancers do not present as a thickened endometrial lining. The other position, held by clinicians who favor the prior, longer-standing ACOG framework, argues this shift will lead to a large number of unnecessary, uncomfortable, and sometimes technically difficult biopsies in women whose bleeding has a benign explanation, without a proportionate improvement in cancer detection.

What the research shows, and which source each finding rests on

In a randomized trial of postmenopausal women starting continuous-combined estradiol/norethisterone acetate hormone therapy, unscheduled bleeding or spotting was reported by 37% of women at 3 months and 30% at 6 months, falling to 26% at 12 months and 7% at 18 months, showing that breakthrough bleeding is genuinely common early on and becomes progressively less frequent as the endometrium adjusts.

?[1]

In a randomized, double-blind comparison of two continuous-combined hormone therapy regimens, the average number of bleeding days fell significantly over the first four months of treatment and then leveled off, and women who started with a thicker baseline endometrium had more bleeding days before reaching amenorrhea.

?[2]

ACOG guidance on evaluating postmenopausal bleeding states that when an initial round of testing (ultrasound or endometrial sampling) does not explain the bleeding, persistent or recurrent bleeding specifically warrants further evaluation such as hysteroscopy with dilation and curettage, rather than being treated as a one-time event that needs no further follow-up.

?[3]

A 2026 clinical perspective published in Menopause, responding to a revision of ACOG guidance that places more emphasis on endometrial tissue sampling, specifically flags women using menopausal hormone therapy as a population in which the newer, more invasive default approach carries particular practical and clinical trade-offs.

?[4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Sample more, sample early

The current, more aggressive ACOG position on endometrial evaluation

The revised guidance leans toward combined ultrasound and endometrial sampling for most patients with postmenopausal bleeding, partly driven by evidence that some endometrial cancers with abnormal p53 status present with a thin, reassuring-looking endometrial lining on ultrasound, meaning a thickness-only threshold can miss them.

?[4]?[5]

Ultrasound-based triage remains appropriate for most women

Clinicians who favor the prior, longer-standing ACOG framework

When the endometrium is fully visualized and measures 4 mm or less by transvaginal ultrasound, with no persistent bleeding, this has a very high negative predictive value for endometrial cancer; routinely escalating to tissue sampling in that situation, especially in women on hormone therapy or who have never given birth, where sampling can be technically difficult, creates a real burden of unnecessary invasive procedures without a proportionate benefit.

?[3]?[4]

What would settle it: Prospective studies that stratify postmenopausal bleeding evaluation strategies by molecular or pathological risk markers (such as p53 status) rather than by endometrial thickness alone, and that directly compare cancer-detection rates, false-negative rates, and rates of unnecessary invasive procedures between an ultrasound-first pathway and a sampling-first pathway, ideally with a subgroup specific to women on hormone therapy.

What is really going on here

  1. Does my bleeding pattern match the known settling-in timeline (lighter, decreasing over the first several months) or does it look different (heavy, painful, or restarting after it had stopped)?
  2. Has my clinician actually looked at my endometrium (by ultrasound or tissue sampling), or was 'it's probably just adjustment' said without any evaluation at all?
  3. If an initial test comes back reassuring but the bleeding continues or comes back, is there a plan for what happens next, rather than one test being treated as the final answer?

Questions for your doctor

  1. Based on how many months I've been on this hormone therapy regimen, is my bleeding still within the expected settling-in window, or has it gone on long enough that it should be evaluated?
  2. Should we do a transvaginal ultrasound, an endometrial biopsy, or both, given my specific bleeding pattern and risk factors?
  3. If my first test comes back normal but the bleeding continues or restarts, what is the plan, and when should I come back?
  4. Could adjusting my regimen or dose (for example, switching from cyclic to continuous-combined, or changing the progestogen) reduce this bleeding, or does the bleeding itself need to be evaluated first regardless?

Questions with no answer yet

How should the classic 3-6 month 'expected settling-in' window for breakthrough bleeding be reconciled with newer guidance favoring routine endometrial tissue sampling? Does a woman on hormone therapy whose bleeding is still within the traditional settling-in timeframe still need tissue sampling under the revised approach, or does the older expectant window still apply specifically to her?

Mixed

What is known: Older frameworks explicitly treated bleeding in the first several months of a new continuous-combined regimen as expected and did not automatically trigger tissue sampling, while the most recent revision to ACOG guidance pushes toward broader use of endometrial sampling for postmenopausal bleeding in general. How the two frameworks should be reconciled specifically for a woman still inside her early hormone-therapy adjustment window has not been directly studied.

What would test it: A prospective study that applies the newer, sampling-forward approach specifically to women within their first 3-6 months of continuous-combined hormone therapy, and compares cancer-detection rates and procedure burden against the older expectant-management approach in that specific population.

Do newer or lower-dose hormone therapy combinations, including transdermal estradiol paired with oral micronized progesterone (increasingly common in current prescribing), follow a similar early bleeding timeline to the oral conjugated-estrogen/medroxyprogesterone-acetate and estradiol/norethisterone-acetate regimens studied in the available randomized trials?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The randomized trials with detailed month-by-month bleeding-timeline data available were conducted with oral continuous-combined regimens (conjugated estrogens with medroxyprogesterone acetate, or estradiol with norethisterone acetate). Dedicated bleeding-timeline data for transdermal estradiol combined with micronized progesterone were not identified in this review.

What would test it: A prospective study tracking bleeding days and time to amenorrhea, month by month, specifically in women starting transdermal estradiol with oral micronized progesterone, using the same methodology as the earlier oral-regimen trials.

Sources

  1. 1.Limpaphayom KK, Bunyavejchevin S, J Med Assoc Thai 2000;83(4):407-16Not rated
  2. 2.Odmark IS, Jonsson B, Backstrom T, Am J Obstet Gynecol 2001;184(6):1131-8Not rated
  3. 3.ACOG Committee Opinion No. 734, Obstet Gynecol 2018;131(5):e124-e129Not rated
  4. 4.Goldstein SR, Menopause 2026Not rated
  5. 5.Wagar MK et al., Obstet Gynecol 2025;146(6):881-887Not rated

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides